HNP Capital’s GSK GSK Stock Holding History

HNP Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,548	Closed	-$337K	–	189
2020 Q1	$337K	Buy	+6,548	New	+$349K	0.05%	183

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HNP Capital's GSK Position: Q2 2020 in Review

HNP Capital sold out of GSK (GSK) in Q2 2020, closing a stake of 6,548 shares — an estimated $337K sold.

HNP Capital first reported a position in GSK in Q1 2020 and held it in 1 quarter. The position peaked at $337K in Q1 2020. 840 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

HNP Capital reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
HNP Capital sold 6,548 GSK shares in Q2 2020, an estimated $337K.
HNP Capital first reported a position in GSK in Q1 2020 and held it in 1 quarter.
HNP Capital's GSK position peaked at $337K in Q1 2020.
840 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on HNP Capital's 13F filing for Q2 2020, filed 6 Jul 2020.